DE60210413D1 - Zusammensetzungen zur immunisierung sowie deren verwendung - Google Patents

Zusammensetzungen zur immunisierung sowie deren verwendung

Info

Publication number
DE60210413D1
DE60210413D1 DE60210413T DE60210413T DE60210413D1 DE 60210413 D1 DE60210413 D1 DE 60210413D1 DE 60210413 T DE60210413 T DE 60210413T DE 60210413 T DE60210413 T DE 60210413T DE 60210413 D1 DE60210413 D1 DE 60210413D1
Authority
DE
Germany
Prior art keywords
compositions
immunizing
present
methods
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210413T
Other languages
English (en)
Other versions
DE60210413T2 (de
Inventor
A Emery
E Straub
E Zammert
K Kallevig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitopix LLC
Original Assignee
Epitopix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26947345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60210413(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epitopix LLC filed Critical Epitopix LLC
Application granted granted Critical
Publication of DE60210413D1 publication Critical patent/DE60210413D1/de
Publication of DE60210413T2 publication Critical patent/DE60210413T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/827—Bacterial vaccine for fish
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
DE60210413T 2001-01-03 2002-01-03 Zusammensetzungen zur immunisierung sowie deren verwendung Expired - Lifetime DE60210413T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25950401P 2001-01-03 2001-01-03
US259504P 2001-01-03
US26289601P 2001-01-19 2001-01-19
US262896P 2001-01-19
PCT/US2002/000188 WO2002053180A2 (en) 2001-01-03 2002-01-03 Immunizing compositions and methods of use

Publications (2)

Publication Number Publication Date
DE60210413D1 true DE60210413D1 (de) 2006-05-18
DE60210413T2 DE60210413T2 (de) 2006-09-07

Family

ID=26947345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210413T Expired - Lifetime DE60210413T2 (de) 2001-01-03 2002-01-03 Zusammensetzungen zur immunisierung sowie deren verwendung

Country Status (14)

Country Link
US (16) US20030036639A1 (de)
EP (1) EP1353689B9 (de)
AT (1) ATE322288T1 (de)
AU (1) AU2002239820C1 (de)
BR (1) BR0206293B1 (de)
CA (2) CA2708949C (de)
CY (1) CY1105563T1 (de)
DE (1) DE60210413T2 (de)
DK (1) DK1353689T3 (de)
ES (1) ES2265488T3 (de)
MX (1) MXPA03006038A (de)
NZ (1) NZ526786A (de)
PT (1) PT1353689E (de)
WO (1) WO2002053180A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
DK0749321T3 (da) * 1994-02-09 2007-03-12 Epitopix Llc Aktiv immunisering under anvendelse af et sideroforreceptorprotein
US7875733B2 (en) * 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US20030036639A1 (en) * 2001-01-03 2003-02-20 Emery Daryll A. Immunizing compositions and methods of use
EP1678316B1 (de) 2003-09-19 2011-08-17 Epitopix, LLC Campylobacter-polypeptide und verwendungsverfahren
US7544376B2 (en) * 2004-07-30 2009-06-09 Sartec Corporation Methods and compositions for increasing milk production in animals
MX2007001886A (es) 2004-08-25 2007-04-24 Epitopix Llc Polipeptidos de fusobacteria y metodos de uso.
JP2008528512A (ja) 2005-01-21 2008-07-31 エピトピックス，リミティド ライアビリティ カンパニー エルシニアｓｐｐ．ポリペプチド及び使用方法
AU2012244060B2 (en) * 2005-02-14 2015-08-20 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
AU2015258239B2 (en) * 2005-02-14 2017-08-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
EP2759307B1 (de) * 2006-03-29 2016-11-09 Merial Limited Impfstoff gegen Streptokokken
WO2008111943A2 (en) * 2006-05-12 2008-09-18 The United States Of America, As Represented By The Secretary Of The Navy Secreted campylobacter flagella coregulated proteins as immunogens
EP2344224A2 (de) * 2008-08-25 2011-07-20 Koninklijke Philips Electronics N.V. Schnittstellen für patientenbeatmung
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2011037444A2 (es) * 2009-09-28 2011-03-31 Carlos Alberto Barcelo Rojas Método de palpación de los estadios fisioreproductivos del útero
US20110129479A1 (en) * 2009-12-02 2011-06-02 Tobin Monte B Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same
CN102205117B (zh) * 2011-05-19 2013-12-18 新疆维吾尔自治区畜牧科学院兽医研究所 奶牛乳房炎金黄色葡萄球菌-大肠埃希氏菌二联多价疫苗及其制备方法
WO2013091898A1 (en) * 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
KR20160014584A (ko) 2013-03-13 2016-02-11 코어 파마슈티칼스 디벨롭먼트 컴퍼니 염증 치료용 면역-변형된 입자
CA2991907A1 (en) 2015-07-10 2017-01-19 Douglas T. Burkhardt Proteins and immunizing compositions containing klebsiella proteins and methods of use
US11235049B2 (en) 2015-11-09 2022-02-01 Epitopix, Llc Polypeptides of fusobacterium and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10905748B2 (en) * 2018-04-16 2021-02-02 Vets Plus, Inc. Ovotransferrin treatment for the reproductive tract
KR102151962B1 (ko) * 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도
CA3175456A1 (en) * 2020-03-24 2021-09-30 Byung Chul Ahn Method of producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof
US20210353732A1 (en) * 2020-05-14 2021-11-18 Zivo Bioscience, Inc. Use of tlr4 modulator in the treatment of coccidiosis
WO2023076623A1 (en) 2021-10-29 2023-05-04 Vaxxinova Us Methods and compositions for preventing infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US197350A (en) * 1877-11-20 Improvement in shoes
US197869A (en) * 1877-12-04 Improvement in the manufacture of glass buttons
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4167560A (en) * 1977-04-12 1979-09-11 Texas Vet Lab, Inc. Polyvalent shipping fever vaccine
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4530963A (en) * 1982-08-20 1985-07-23 Devoe-Holbein International, N.V. Insoluble chelating compositions
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
GB2202851B (en) 1987-03-24 1990-12-19 Nat Res Dev Proteinaceous material of p. haemolytica and vaccine against pasteurella
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
FR2644346B1 (fr) 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5141743A (en) * 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
AU4114893A (en) * 1992-04-27 1993-11-29 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US5578314A (en) * 1992-05-29 1996-11-26 The Regents Of The University Of California Multiple layer alginate coatings of biological tissue for transplantation
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
DK0749321T3 (da) * 1994-02-09 2007-03-12 Epitopix Llc Aktiv immunisering under anvendelse af et sideroforreceptorprotein
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6121037A (en) 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6048539A (en) 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6902747B1 (en) * 2000-05-03 2005-06-07 Westfaliasurge, Inc. Iodine-propylene glycol teat dip
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
US20030036639A1 (en) * 2001-01-03 2003-02-20 Emery Daryll A. Immunizing compositions and methods of use
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US6984503B1 (en) * 2002-06-27 2006-01-10 The United States Of America As Represented By The Secretary Of The Agriculture Use of recombinant bovine CD14 in the treatment and prevention of coliform mastitis in dairy cows
EP1678316B1 (de) 2003-09-19 2011-08-17 Epitopix, LLC Campylobacter-polypeptide und verwendungsverfahren
MX2007001886A (es) 2004-08-25 2007-04-24 Epitopix Llc Polipeptidos de fusobacteria y metodos de uso.
JP2008528512A (ja) 2005-01-21 2008-07-31 エピトピックス，リミティド ライアビリティ カンパニー エルシニアｓｐｐ．ポリペプチド及び使用方法
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
US7913151B1 (en) * 2006-05-26 2011-03-22 Pmc-Sierra, Inc. Forward error correction with self-synchronous scramblers
CA2991907A1 (en) * 2015-07-10 2017-01-19 Douglas T. Burkhardt Proteins and immunizing compositions containing klebsiella proteins and methods of use

Also Published As

Publication number Publication date
CA2433561A1 (en) 2002-07-11
BR0206293B1 (pt) 2015-01-20
US20030036639A1 (en) 2003-02-20
DK1353689T3 (da) 2006-07-31
CY1105563T1 (el) 2010-07-28
US20030211118A1 (en) 2003-11-13
DE60210413T2 (de) 2006-09-07
ES2265488T3 (es) 2007-02-16
US8425916B2 (en) 2013-04-23
US20110200616A1 (en) 2011-08-18
PT1353689E (pt) 2006-08-31
US20170087238A1 (en) 2017-03-30
US20060165718A1 (en) 2006-07-27
US20040265329A1 (en) 2004-12-30
US20110200637A1 (en) 2011-08-18
US7160549B2 (en) 2007-01-09
US7943150B2 (en) 2011-05-17
EP1353689B1 (de) 2006-04-05
NZ526786A (en) 2006-02-24
WO2002053180A3 (en) 2003-03-13
CA2708949C (en) 2016-03-08
US20110206733A1 (en) 2011-08-25
US7341732B2 (en) 2008-03-11
US20090081236A1 (en) 2009-03-26
MXPA03006038A (es) 2005-02-14
US7943151B2 (en) 2011-05-17
US7147857B2 (en) 2006-12-12
US8575315B2 (en) 2013-11-05
US20090162402A1 (en) 2009-06-25
CA2433561C (en) 2014-04-01
US20040197350A1 (en) 2004-10-07
BR0206293A (pt) 2005-10-25
US20130217048A1 (en) 2013-08-22
US8637048B2 (en) 2014-01-28
CA2708949A1 (en) 2002-07-11
US20120195899A1 (en) 2012-08-02
US8282941B2 (en) 2012-10-09
US8993252B2 (en) 2015-03-31
US20040197869A1 (en) 2004-10-07
AU2002239820B2 (en) 2007-08-23
EP1353689A2 (de) 2003-10-22
ATE322288T1 (de) 2006-04-15
AU2002239820C1 (en) 2008-07-10
WO2002053180A2 (en) 2002-07-11
US20120195898A1 (en) 2012-08-02
US7138125B2 (en) 2006-11-21
EP1353689B9 (de) 2006-06-28
US7138124B2 (en) 2006-11-21
US7371393B2 (en) 2008-05-13
US20030206922A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
DE60210413D1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
MY131890A (en) Piperidine compounds
IL189629A0 (en) Compositions containing human ctla-4 antibodies
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
CY1105879T1 (el) Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
WO2005026137A3 (en) Modulators of atp-binding cassette transporters
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
UA86042C2 (en) Substituted indazole-o-glucosides
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
ATE440825T1 (de) Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE464910T1 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition